BioPharmSignal logoBioPharmSignal

Biotech News

PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights

PMV Pharmaceuticals (PMVP)PMV PharmaceuticalsEarnings

Rezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53 Y220C positive ovarian cancer New England Journal of Medicine published first-in-human rezatapopt data showing selective reactivation of mutant p53 in advanced solid tumors Rezatapopt New

Related news

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

ZNTLZentalis2026-08-06 20:05 EST

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

GERNGeron2026-08-05 11:00 EST

Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

EXELExelixis2026-08-05 20:05 EST

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

INVAInnoviva2026-08-05 20:05 EST

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

RVMDRevolution Medicines2026-08-05 20:02 EST

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

BNTXBioNTech2026-08-04 10:45 EST

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

View all latest news

PMV Pharmaceuticals

Mutant p53 Precision Oncology PMV Pharmaceuticals develops small molecules that restore activity to specific mutant forms of the tumor suppressor p53. Rezatapopt Rezatapopt selectively binds the TP53 Y220C mutant and is designed to restore wild-type p53 structure and tumor-suppressor function. Ovarian Cancer Lead Indication The PYNNACLE...

Recent company news

PMVPPMV Pharmaceuticals2026-05-12 12:00 EST

PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights

PMVPPMV Pharmaceuticals2026-04-22 12:00 EST

PMV Pharmaceuticals Announces Board Chair Transition

PMVPPMV Pharmaceuticals2026-03-06 13:00 EST

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

PMVPPMV Pharmaceuticals2026-02-26 13:00 EST

New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors

PMVPPMV Pharmaceuticals2025-11-12 13:01 EST

PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights

Stock data

Close
1.18 USD
Market cap
62.93M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States